Selection for Oncotype Dx testing among young women with early-stage ER+/HER2-breast cancer.

被引：3
|
作者：
Poorvu, Philip Daniel
Gelber, Shari I.
Rosenberg, Shoshana M.
Ruddy, Kathryn Jean
Tamimi, Rulla
Peppercorn, Jeffrey M.
Schapira, Lidia
Borges, Virginia F.
Come, Steven E.
Collins, Laura C.
Warner, Ellen
Partridge, Ann H.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin, Dept Oncol, Rochester, MN USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Stanford Canc Ctr, Palo Alto, CA USA
[6] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[7] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[8] Harvard Med Sch, Boston, MA USA
[9] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
533
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2-Breast Cancer
    Song, Ran
    Lee, Dong-Eun
    Lee, Eun-Gyeong
    Lee, Seeyoun
    Kang, Han-Sung
    Han, Jai Hong
    Lee, Keun Seok
    Sim, Sung Hoon
    Chae, Heejung
    Kwon, Youngmee
    Woo, Jaeyeon
    Jung, So-Youn
    CANCERS, 2023, 15 (18)
  • [2] Genomic risk assessment with Oncotype DX in young women (age ≤ 40 years old) with early-stage ER+/HER2-/N0 breast cancer
    Iosifidou, R.
    Xepapadakis, G.
    Venizelos, V.
    Markopoulos, C.
    Papazisis, K.
    Tsoulos, N.
    Kapetsis, G.
    Giannoulakis, S.
    Paraskeva, M.
    Kaparelou, M.
    Lainakis, G.
    Fotarelli, A.
    Pavlidou, F.
    Fountzilas, E.
    Saloustros, E.
    Karageorgopoulou, S.
    Triantafillidou, S.
    Intzes, S.
    Koinis, F.
    BREAST, 2025, 80
  • [3] MODERN CHEMOTHERAPY USE AMONG YOUNG WOMEN WITH EARLYSTAGE ER+/HER2-BREAST CANCER
    Poorvu, Philip
    Gelber, Shari
    Rosenberg, Shoshana
    Ruddy, Kathryn
    Tamimi, Rulla
    Peppercorn, Jeffrey
    Schapira, Lidia
    Borges, Virginia
    Come, Steven
    Collins, Laura
    Warner, Ellen
    Partridge, Ann
    BREAST, 2018, 41 : S18 - S18
  • [4] Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk
    Sarkar, Swarnavo
    Schechter, Clyde
    Kurian, Allison W.
    Caswell-Jin, Jennifer L.
    Jayasekera, Jinani
    Mandelblatt, Jeanne S.
    NPJ BREAST CANCER, 2025, 11 (01)
  • [5] TILs in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Viale, G.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 3 - 3
  • [6] Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer
    Roberts, Megan C.
    Weinberger, Morris
    Dusetzina, Stacie B.
    Dinan, Michaela A.
    Reeder-Hayes, Katherine E.
    Carey, Lisa A.
    Troester, Melissa A.
    Wheeler, Stephanie B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02) : 130 - +
  • [7] Incidence of Pulmonary Embolism Among Postmenopausal (PM) Women with ER+/HER2-Breast Cancer
    Zhou, Xiaofeng
    de Luise, Cynthia
    Shen, Rongjun
    Bate, Andrew
    Gatto, Nicolle
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 372 - 373
  • [8] Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer.
    Chen, C.
    Patt, D. A.
    Kazzaz, D. R.
    Shankleton, J.
    Forsyth, M. T.
    Ganesh, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Role of androgen receptor expression in early stage ER+/PgR-/HER2-breast cancer
    Tagliaferri, Barbara
    Quaquarini, Erica
    Palumbo, Raffaella
    Balletti, Emanuela
    Presti, Daniele
    Malovini, Alberto
    Agozzino, Manuela
    Teragni, Cristina Maria
    Terzoni, Andrea
    Bernardo, Antonio
    Villani, Laura
    Sottotetti, Federico
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [10] Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer
    Jon Whitney
    German Corredor
    Andrew Janowczyk
    Shridar Ganesan
    Scott Doyle
    John Tomaszewski
    Michael Feldman
    Hannah Gilmore
    Anant Madabhushi
    BMC Cancer, 18
12345